Tony

Wiemelt, PhD

Associate Director

HIGHLIGHTS

  • Implemented 5 programs integrating pharmacogenomics and cutting-edge precision medicine technology into daily practice at Penn Medicine.
  • Orchestrated executive management of Merck’s Oncology and Infectious Disease franchises.
  • Developed and helped implement Merck’s R&D SharePoint IT platform, improving information flow, accountability, and project tracking throughout the organization.

Tony has worked in the pharmaceutical/healthcare industry for more than 15 years as a project and portfolio management leader. At Foresite Capital, he is a member of the investment team and focuses on company research and due diligence. 

He joined Foresite Capital from University of Pennsylvania Health System, where he was the Chief Administrative Officer for Precision Medicine. While at Penn, Tony developed and implemented detailed business plans for strategic, programmatic, and operational aspects of Penn Medicine’s Precision Medicine program across multiple clinical areas, including Oncology, Cardiovascular, Ob/Gyn, and Neurology.

Prior to Penn, Tony worked at Merck Research Laboratories across multiple therapeutic areas and was the project/portfolio manager for development projects across all phases of development. Within Global Project Management, Tony held positions as Director, Infectious Disease Portfolio as well as the Director, Oncology Portfolio, two of Merck’s key franchises. In addition, Tony was responsible for coordinating project management of the scientific due diligence for all potential licensing candidates for Merck Research Laboratories.  

Tony received his PhD in Neuroscience from the University of Pennsylvania. His research focused on the role of second messenger systems (cyclic AMP) in the regulation of development of neural supportive tissues (oligodendrocytes). He completed his post-doctoral fellowship at the Department of Cell & Molecular Biology, University of Pennsylvania, where he explored zebrafish neural development and the role of bone morphogenetic proteins in the specification of neural tissues and mechanisms of gene action in early neural patterning.